Related Experiment Videos
[Comparative studies of tocainide and propafenone in the treatment of ventricular arrhythmias]
Abstract:
In 15 patients with ventricular arrhythmias without previous treatment the effectiveness of 2-amino-2',6'-dimethylpropionanilide (tocainide, Xylotocan) and propafenone was compared in a cross-over-trial. 14 Patients had ventricular arrhythmias of the Lown classification IVa-V, 1 patient of Lown classification III. In 3 patients after the first course of tocainide resp. propafenone no change in therapy was made because of reducing the Lown classification by two or more grades. All patients had 24-h-ECG-Holter-Monitoring before, at the 4th day before change of therapy, and at the 9th day of therapy. Following relevant results were found: Both tocainide (p less than 0,005) and propafenone (p less than 0,05) reduce the total amount of ventriculare premature beats (VPB) without statistical significant difference between both substances. Both tocainide (p less than 0,005) and propafenone (p less than 0,02) reduce the number of isolated polytope VPB without statistical significant difference between both substances. Only tocainide (p less than 0,005) reduces couplets, but there was no statistical significant difference to propafenone. Neither tocainide nor propafenone alone was able to make total suppression of the ventricular arrhythmias in the patients included in this study. Both substances were able to lower VPB buth with a more favourable but statistically not significant therapeutic effect of tocainide.
Insights
Tocainide and propafenone effectively reduce ventricular premature beats (VPBs) in patients with arrhythmias. While both drugs showed efficacy, tocainide demonstrated a trend towards a more favorable outcome, though neither achieved total arrhythmia suppression.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Ventricular arrhythmias pose a significant clinical challenge.
- Effective antiarrhythmic drug therapy is crucial for managing these conditions.
Purpose of the Study:
- To compare the efficacy of tocainide and propafenone in treating ventricular arrhythmias.
- To evaluate the reduction in ventricular premature beats (VPBs) and specific arrhythmia patterns.
Main Methods:
- A cross-over trial involving 15 patients with ventricular arrhythmias.
- 24-hour ECG-Holter monitoring was performed before and during therapy.
- Tocainide and propafenone effectiveness was assessed based on VPB reduction and Lown classification changes.
Main Results:
- Both tocainide and propafenone significantly reduced the total number of VPBs and isolated polytope VPBs.
- Tocainide showed a significant reduction in couplets, a finding not statistically different from propafenone.
- Neither drug achieved complete suppression of ventricular arrhythmias in the study population.
Conclusions:
- Tocainide and propafenone are effective in reducing ventricular arrhythmias.
- Tocainide exhibited a trend towards a more favorable therapeutic effect, although not statistically significant.
- Further research may be warranted to explore the comparative benefits of tocainide in specific patient subgroups.